Publication number: 20150246913
Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.
Type:
Application
Filed:
October 18, 2013
Publication date:
September 3, 2015
Applicants:
Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Nathanael Gray, Steven Balk, Qingsong Liu, Sen Chen
Publication number: 20080255112
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf, EGFR, Fes, FGFR3, Fms, Fyn, IGF-IR, IR, IKK?, IKK?, JAK2, JAK3, KDR, Lck, Met, p70S6k, Ros, Rsk1, SAPK2?, SAPK2?, SAPK3, SIK, Tie2, TrkB and/or WNK3 kinases.
Type:
Application
Filed:
June 30, 2006
Publication date:
October 16, 2008
Inventors:
Guobao Zhang, Pingda Ren, Xia Wang, Nathanael Gray, Taebo Sim